These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 37227449)

  • 21. Advances in engineering and delivery strategies for cytokine immunotherapy.
    Bohmer M; Xue Y; Jankovic K; Dong Y
    Expert Opin Drug Deliv; 2023 May; 20(5):579-595. PubMed ID: 37104673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Engineering cytokines for cancer immunotherapy: a systematic review.
    Fu Y; Tang R; Zhao X
    Front Immunol; 2023; 14():1218082. PubMed ID: 37483629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nanomaterial-Based Drug Delivery Systems: A New Weapon for Cancer Immunotherapy.
    Jiang Z; Zhang W; Zhang J; Liu T; Xing J; Zhang H; Tang D
    Int J Nanomedicine; 2022; 17():4677-4696. PubMed ID: 36211025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beyond the cell: novel noncellular immunotherapy approaches to multiple myeloma.
    Holstein SA
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):173-179. PubMed ID: 36485098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel strategy to generate immunocytokines with activity-on-demand using small molecule inhibitors.
    Rotta G; Gilardoni E; Ravazza D; Mock J; Seehusen F; Elsayed A; Puca E; De Luca R; Pellegrino C; Look T; Weiss T; Manz MG; Halin C; Neri D; Dakhel Plaza S
    EMBO Mol Med; 2024 Apr; 16(4):904-926. PubMed ID: 38448543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IL-10 in cancer: an essential thermostatic regulator between homeostatic immunity and inflammation - a comprehensive review.
    Rallis KS; Corrigan AE; Dadah H; Stanislovas J; Zamani P; Makker S; Szabados B; Sideris M
    Future Oncol; 2022 Sep; 18(29):3349-3365. PubMed ID: 36172856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.
    Hess C; Neri D
    Protein Eng Des Sel; 2014 Jun; 27(6):207-13. PubMed ID: 24795343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Smart drug delivery systems to overcome drug resistance in cancer immunotherapy.
    Yi W; Yan D; Wang D; Li Y
    Cancer Biol Med; 2023 May; 20(4):248-67. PubMed ID: 37144580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stimuli-responsive nanoassemblies for targeted delivery against tumor and its microenvironment.
    Sia CS; Lim HP; Tey BT; Goh BH; Low LE
    Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188779. PubMed ID: 35977690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanoparticle mediated cancer immunotherapy.
    Gupta J; Safdari HA; Hoque M
    Semin Cancer Biol; 2021 Feb; 69():307-324. PubMed ID: 32259643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies.
    Chester C; Sanmamed MF; Wang J; Melero I
    Blood; 2018 Jan; 131(1):49-57. PubMed ID: 29118009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytokine/Antibody Fusion Protein Design and Evaluation.
    Fabilane CS; Stephenson AC; Leonard EK; VanDyke D; Spangler JB
    Curr Protoc; 2024 May; 4(5):e1061. PubMed ID: 38775006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunocytokines are a promising immunotherapeutic approach against glioblastoma.
    Weiss T; Puca E; Silginer M; Hemmerle T; Pazahr S; Bink A; Weller M; Neri D; Roth P
    Sci Transl Med; 2020 Oct; 12(564):. PubMed ID: 33028706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.
    Alderson KL; Sondel PM
    J Biomed Biotechnol; 2011; 2011():379123. PubMed ID: 21660134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunocytokines: a promising approach to cancer immunotherapy.
    Lode HN; Xiang R; Becker JC; Gillies SD; Reisfeld RA
    Pharmacol Ther; 1998 Dec; 80(3):277-92. PubMed ID: 9888698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Revitalizing Cytokine-Based Cancer Immunotherapy through Advanced Delivery Systems.
    Chen P; Paraiso WKD; Cabral H
    Macromol Biosci; 2023 Dec; 23(12):e2300275. PubMed ID: 37565723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential.
    Ceci C; Lacal PM; Graziani G
    Pharmacol Ther; 2022 Aug; 236():108106. PubMed ID: 34990642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges.
    Martin JD; Cabral H; Stylianopoulos T; Jain RK
    Nat Rev Clin Oncol; 2020 Apr; 17(4):251-266. PubMed ID: 32034288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant immunocytokines targeting the mouse transferrin receptor: construction and biological activities.
    Dreier T; Lode HN; Xiang R; Dolman CS; Reisfeld RA; Kang AS
    Bioconjug Chem; 1998; 9(4):482-9. PubMed ID: 9667950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.